Evidence map›Paper›PMID 39972345›Full record

ArticleCancer cell international2025

EGFR-to-Src family tyrosine kinase switching in proliferating-DTP TNBC cells creates a hyperphosphorylation-dependent vulnerability to EGFR TKI.

Nazia Chaudhary, Bhagya Shree Choudhary, Anusha Shivashankar, Subhakankha Manna, Khyati Ved, Shagufa Shaikh, Sonal Khanna, Jeetnet Baar, Jagruti Dani, Sarthak Sahoo and 3 more

Abstract read
In one paragraph

Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Nazia ChaudharyAdvanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi-Mumbai, Maharashtra, India.
Bhagya Shree ChoudharyAdvanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi-Mumbai, Maharashtra, India.
Anusha ShivashankarAdvanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi-Mumbai, Maharashtra, India.
Subhakankha MannaAdvanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi-Mumbai, Maharashtra, India.
Khyati VedAdvanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi-Mumbai, Maharashtra, India.
Shagufa ShaikhAdvanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi-Mumbai, Maharashtra, India.
Sonal KhannaAdvanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi-Mumbai, Maharashtra, India.
Jeetnet BaarAdvanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi-Mumbai, Maharashtra, India.
Jagruti DaniAdvanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi-Mumbai, Maharashtra, India.
Sarthak SahooCentre for BioSystems Science and Engineering, Indian Institute of Science, Bengaluru, 560012, India.
R SoundharyaCentre for BioSystems Science and Engineering, Indian Institute of Science, Bengaluru, 560012, India.
Mohit Kumar JollyCentre for BioSystems Science and Engineering, Indian Institute of Science, Bengaluru, 560012, India.
Nandini VermaAdvanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi-Mumbai, Maharashtra, India. nverma@actrec.gov.in.

Funding

Department of Atomic Energy, Government of India No.1/3(7)/2020/TMC/R&D-II/8823, 1/3(6)/2020/TMC/R&D -II/ 3805
6 · The paper itself

Abstract

Triple-Negative Breast Cancer (TNBC) is the most aggressive type of breast malignancy, with chemotherapy as the only mainstay treatment. TNBC patients have the worst prognoses as a large fraction of them do not achieve complete pathological response post-treatment and develop drug-resistant residual disease. Molecular mechanisms that trigger proliferation in drug-resistant chemo-residual TNBC cells are poorly understood due to the lack of investigations using clinically relevant cellular models. In this study, we have established TNBC subtype-specific cellular models of proliferating drug-tolerant persister (PDTP) cells using different classes of chemotherapeutic agents that recapitulate clinical residual disease with molecular heterogeneity. Analysis of total phospho-tyrosine signals in TNBC PDTPs showed an enhanced phospho-tyrosine content compared to the parental cells (PC). Interestingly, using mass-spectrometry analysis, we identified a dramatic decrease in epidermal growth factor receptor (EGFR) expression in the PDTPs, while the presence of hyper-activated tyrosine phosphorylation of EGFR compared to PC. Further, we show that EGFR has enhanced lysosomal trafficking in PDTPs with a concomitant increase in N-Myc Downstream Regulated-1 (NDRG1) expression that co-localizes with EGFR to mediate receptor degradation. More surprisingly, we found that reduced protein levels of EGFR are coupled with a robust increase in Src family kinases, including Lyn and Fyn kinases, that creates a hyper-phosphorylation state of EGFR-Src tyrosine kinases axis in PDTPs and mediates downstream over-activation of STAT3, AKT and MAP kinases. Moreover, paclitaxel-derived PDTPs show increased sensitivity to EGFR TKI Gefitinib and its combination with paclitaxel selectively induced cell death in Paclitaxel-derived PDTP (PDTP-P) TNBC cells and 3D spheroids by strongly downregulating phosphorylation of EGFR-Src with concomitant downregulation of Lyn and Fyn tyrosine kinases. Collectively, this study identifies a unique hyper-phosphorylation cellular state of TNBC PDTPs established by switching of EGFR-Src family tyrosine kinases, creating a vulnerability to EGFR TKI.

Indexed as

Combination therapyEGFRProliferating drug-tolerant persister (PDTPs)Src family kinasesTNBC

Identifiers

PMID39972345
PMCPMC11841279

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.